We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Supreme Court is seeking advice from the U.S. government on whether it should review a federal antitrust lawsuit triggered by a reverse-payment deal that delayed the launch of generic tamoxifen.
The FTC will continue to pursue an anticompetitive case against Barr Laboratories following a federal district court ruling rejecting the generic firm’s motion to dismiss the case, agency sources said.
Plaintiffs are asking the Supreme Court to review the dismissal of a case to determine the legality of reverse-payment agreements, where brand drugmakers pay generic rivals to keep their low-cost versions of prescription products off the market.
The FTC is set to approve a plan proposed by Hospira to acquire Australia-based generic firm Mayne Pharma for $2 billion, as long as certain conditions are met, the agency has announced.
In the last year, more out-of-court settlements between generic and brand companies involved reverse payment deals than in the two previous years combined, according to a new FTC report.
The FTC has given Watson Pharmaceuticals permission to buy Andrx as long as the two sell off certain assets, including Andrx’s portfolio of oral contraceptives.
The FTC has given Watson Pharmaceuticals permission to buy Andrx as long as the two sell off certain assets, including Andrx’s portfolio of oral contraceptives.
The FTC has given Watson Pharmaceuticals permission to buy Andrx as long as the two sell off certain assets, including Andrx’s portfolio of oral contraceptives.
Warner Chilcott is forbidden to enter reverse payment agreements — where brand companies pay generic competitors to delay launching their version of a drug — with generic pharmaceutical companies, under a legal settlement the drugmaker has reached with the FTC.
Barr Pharmaceutical announced Sept. 28 that it is now free to close a deal with Shire, acquiring the rights to Shire’s attention-deficit/
hyperactivity disorder drug Adderall immediate-release (IR) tablets.